About Complix
Complix discovers and develops Alphabodies, a novel and proprietary class of biopharmaceuticals that delivers significant advantages over current protein therapeutic approaches. Alphabodies comprise an alpha-helical coiled coil structure, which makes them ideal protein scaffolds for therapeutic applications as they combine the specificity of antibodies with small molecule-like properties. Alphabodies’ most important advantage is their ability to address currently undruggable extracellular and, in particular, intracellular targets.
Complix is headquartered in Hasselt (Belgium) in the Life Sciences incubator BioVille, and has research facilities in Ghent (Belgium) and in Luxembourg. The Company has a fully owned subsidiary in Luxembourg and a strategic alliance with the public research institute CRP-Santé.
- Industry : Biotechnology
